



**Fresenius Kabi  
Canada Ltd.**

165 Galaxy Blvd, Suite 100  
Toronto, Ontario  
Canada M9W 0C8  
T: 905.770.3711  
F: 844.513.1522  
W: fresenius-kabi.ca

August 1, 2024

## **Moxifloxacin Injection, 400 mg per 250 mL (1.6 mg per mL)** **US-Approved Product – Allocation Update**

Dear Valued Customer,

Fresenius Kabi Canada would like to advise that allocations for **Fresenius Kabi's US-approved Moxifloxacin Injection, 400 mg per 250 mL (1.6 mg per mL)** are reduced effective **August 1, 2024**. Contract customers are allocated **50% of historical monthly demand**.

<b>Fresenius Kabi Product Code</b>	<b>MDP Product Code</b>	<b>McKesson Product Code</b>	<b>Product Description</b>	<b>Allocation Date</b>
850174	978413	190875	Fresenius Kabi's US-approved Moxifloxacin Injection, 400 mg per 250 mL (1.6 mg per mL)	50% Allocation <b>Aug. 1, 2024</b>

We recognize the difficulties and inconvenience that you may encounter as a result of these reduced allocations, and we thank you for your patience and understanding in this matter.

If you have any questions or concerns, please do not hesitate to contact your sales representative.

Sincerely,

Joseph Le  
Associate Director, IV Drugs  
[joseph.le@fresenius-kabi.com](mailto:joseph.le@fresenius-kabi.com)



Scan and register to receive our communications via email.